Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →B grade PMID 42748428
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42765973
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →This review synthesizes evidence on prenatal pre-leukemic origins, secondary mutations, inflammation, immune modulation, and remodeling of hematopoietic niches in pediatric leukemia, while outlining emerging diagnostic and therapeutic approaches.
The supplied review supports an association between inflammatory, immunological, and microenvironmental processes and pediatric leukemia progression; it is reasonable but still inferential to hypothesize that disrupting leukemia-supportive niche signaling or immune modulation could improve therapy or prevent progression in selected patients.
In a single-center retrospective cohort of 46 patients with CSF-confirmed anti-NMDAR encephalitis, 9 (19.6%) had peripheral nervous system involvement, most notably limb weakness and electrophysiologic abnormalities affecting motor pathways or proximal nerve roots.
The evidence supports considering peripheral neurologic assessment and targeted electrophysiology in anti-NMDAR encephalitis patients with limb weakness; it is only an inference that earlier recognition could guide supportive care or immunotherapy decisions, because the study found no significant prognostic association and did not test a PNS-directed treatment strategy.
This narrative review summarizes the biological rationale, Phase 3 and real-world evidence, safety, and remaining evidence gaps for IL-23p19 inhibitors in Crohn’s disease and ulcerative colitis.
Evidence summarized in the record supports selective IL-23p19 inhibition as an effective strategy for moderate-to-severe inflammatory bowel disease; any application to pediatric oncology, such as managing inflammatory comorbidity or treatment-related intestinal inflammation, is speculative and is not evaluated in the supplied record.
In 116 children with fusion gene-positive acute myeloid leukaemia, ddPCR showed slower MRD-negativity conversion, sustained prognostic association at later assessment, and broader genetic-subgroup stratification than MFC, while combining both assays improved risk discrimination.
The reported evidence supports combined ddPCR and MFC as a potentially more precise prognostic strategy; it may enable MRD-guided treatment intensification or de-escalation, but improved treatment outcomes from assay-directed management remain an untested inference in this record.
In a transatlantic multicentre cohort of 103 survivors of paediatric head and neck rhabdomyosarcoma, radiographic dental developmental abnormalities were common and more severe among children diagnosed before age 6.
The evidence supports age at diagnosis as a marker of dental late-effect risk; it is reasonable—but not tested here—to hypothesize that risk-adapted dental surveillance and timely specialist care could reduce the functional consequences of these abnormalities.
This single-center retrospective cohort reports subtype-specific imaging patterns in 144 pediatric ALL patients and associations between selected genetic alterations and disseminated or organ-specific radiological findings.
The evidence shows imaging–genetic associations rather than therapeutic effects; inferentially, validated radiological phenotypes might complement molecular testing for risk stratification or individualized diagnostic evaluation, but treatment selection and outcome improvement were not tested.
In a retrospective cohort of 49 patients, preoperative cyst wall enhancement was strongly associated with local recurrence after gross-total resection of intracranial hemangioblastoma, with recurrence in 8 of 14 enhancement-positive tumors versus none of 30 enhancement-negative tumors.
The evidence supports cyst wall enhancement as a candidate imaging prognostic marker; it may, by inference, help guide surgical attention to the cyst wall or more intensive postoperative surveillance, but the study did not test whether these strategies reduce recurrence.
In a single-center retrospective cohort of 147 children undergoing first allogeneic HCT for acute leukemia, prespecified analyses found no association between five-level neighborhood opportunity and outcomes, while an exploratory comparison linked very low opportunity with inferior overall survival.
The evidence supports neighborhood opportunity as a possible prognostic or risk-stratification factor rather than a treatment target; if the exploratory association is validated, it could motivate testing whether targeted supportive-care or resource interventions improve post-HCT outcomes, but this intervention benefit is inferential and was not evaluated.
In a retrospective cohort of 442 consecutive alloHSCT recipients, elevated pre-transplant and worsening day+30 modified Glasgow Prognostic Scores were independently associated with poorer overall survival and higher non-relapse mortality, with sex-specific risk patterns and conflicting findings for acute graft-versus-host disease.
The evidence supports mGPS as a candidate prognostic biomarker rather than a treatment; it may be inferred that identifying inflammation and nutritional-risk trajectories could guide monitoring or future supportive-care interventions, but the record does not show that mGPS-guided management or modifying mGPS improves outcomes.
This single-institution retrospective study of 208 patients aged 11.7–39.9 years with primary breast sarcoma or malignant/borderline phyllodes tumors reports frequent recurrence, 5-year overall survival of 80.9%, pathogenic mutations in 32.0% of those tested, and an association between mastectomy and worse observed survival.
The evidence identifies prognostic and treatment-selection signals rather than proving a therapeutic strategy: it supports further study of germline testing and surgical decision-making, while the possibility that selected patients could benefit from genetics-informed surveillance or breast-conserving surgery is an inference requiring prospective or carefully controlled multi-institutional validation.
This qualitative study identifies multilevel barriers and facilitators affecting HPV vaccine acceptance among adolescent girls and relevant stakeholders in Punjab, Pakistan, before the country's first national HPV vaccine rollout.
The reported findings support the presence of modifiable social, cultural, trust, and service-delivery determinants of HPV vaccine uptake; it is reasonable—but not tested here—to hypothesize that culturally sensitive counseling, trusted school and religious engagement, and accessible outreach could increase vaccination and ultimately reduce HPV-related cervical cancer.
This prospective UK cohort found frequent, persistent severe vitamin D deficiency and elevated winter parathyroid hormone levels among South Asian adolescents compared with white Caucasian adolescents, alongside lower weekend sun exposure and fewer holidays abroad.
The evidence supports skin type-associated differences in UVR exposure and vitamin D status, but it does not test a treatment; it can only be inferred that tailored sun-exposure guidance or vitamin D interventions might reduce deficiency and secondary hyperparathyroidism, including potentially in pediatric-oncology populations if separately studied.
